More research is required to explore whether the nocebo effect on biosimilar switching may contribute to biologic treatment failure, gastroenterologists say. In a Review article in Rheumatology and Therapy, gastroenterologists and rheumatologists called for more robust and well-designed nonmedical switching studies. The nocebo effect was defined as disease worsening or occurrence of a new or ...
Do biosimilars have a nocebo effect that contributes to treatment failure?
By Mardi Chapman
5 Feb 2020